Allogene therapeutics Contact Number

All Time Past 24 Hours Past Week Past month Post Your Comments?

About Allogene therapeutics Contact Number

Want to learn more about Allogene Therapeutics? Please contact us by phone at 650-457-2700 or by email at [email protected]allogene.com.

Contact US: https://www.allogene.com/contact-us

What is allogene therapeutics?

Allogene Therapeutics is a clinical-stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR T TM) therapies for cancer.

Where can i find more information on allogene clinical trials?

For more information on Allogene clinical trials that may be recruiting, search Allogene at www.clinicaltrials.gov “Expanded Access” refers to the use of an investigational therapy outside of a clinical trial for potential treatment of a serious or life-threatening condition.

Who is the founder and ceo of allogene?

We are led by a world-class management team of industry leaders who have unrivaled experience in the clinical development of cell immunotherapy for cancer. Arie Belldegrun, MD, FACS, is the Executive Chairman and Co-Founder of Allogene.

How is allogene working to cure autologous car t?

WE DON’T JUST SEE THE FUTURE. WE KNOW HOW TO GET THERE. Allogene is working to overcome the limitations of autologous CAR T immunotherapy by developing AlloCAR T™ therapies. The goal of our allogeneic platform is simple: combine gene-editing technology with cutting-edge cell-therapy manufacturing to deliver the clinical benefits of cell therapy.

Allogene

27 People Used

See More ››

Allogene Therapeutics: Allogeneic Cell Therapy

Allogene is working to overcome the limitations of autologous CAR T immunotherapy by developing AlloCAR T™ therapies. The goal of our allogeneic platform is simple: combine gene-editing technology with cutting-edge cell-therapy manufacturing to deliver the clinical benefits of cell therapy.

View Contact ››

Development

36 People Used

See More ››

Information About Allogene Therapeutics

Allogene Therapeutics is a clinical-stage biotechnology company with a single-minded focus on pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR T™) therapies for cancer. Led by world-class management with significant experience in cell therapy, our fully integrated, in-house team of researchers is dedicated to discovery and translational research, development

View Contact ››

Allogene

49 People Used

See More ››

ALLO

Allogene Media/Investor Contact: Christine Cassiano Chief Communications Officer (714) 552-0326 please dial 1 (866) 940-5062 (U.S.) or 1 (409) 216-0618 (International). The conference ID number for the live call is 9435559. About Allogene Therapeutics Allogene Therapeutics, with headquarters in South San Francisco, is a clinical-stage

View Contact ››

Therapy

43 People Used

See More ››

Allogene Therapeutics Company Profile

Allogene Therapeutics is a clinical stage biotechnology company pioneering the development of allogeneic CAR T therapies for cancer. The Company''s portfolio includes rights to 16 pre-clinical CAR T cell therapy targets and UCART19, an allogeneic CAR T therapy candidate currently in Phase 1 development for the treatment of relapsed/refractory acute lymphoblastic leukemia (ALL).

View Contact ››

Allogene

68 People Used

See More ››

Allogene Therapeutics

Allogene Therapeutics to Host Virtual CD19 Forum on May 19, 2021 SOUTH SAN FRANCISCO, Calif., May 12, 2021 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) therapies for cancer will discuss progress on its AlloCAR T platform during a virtual CD19 Forum on May 19, 2021 …

View Contact ››

Allogene

193 People Used

See More ››

Allogene Therapeutics LinkedIn

Allogene Therapeutics

View Contact ››

Allogene

77 People Used

See More ››

EIN 82 3562771

Allogene Therapeutics, Inc. is a corporation in South San Francisco, California. The employer identification number (EIN) for Allogene Therapeutics, Inc. is 823562771. EIN for organizations is sometimes also referred to as taxpayer identification number or TIN or simply IRS Number. It is one of the corporates which submit 10-K filings with the SEC.

View Contact ››

Company

62 People Used

See More ››

Allogene Therapeutics Inc

Company profile page for Allogene Therapeutics Inc including stock price, company news, press releases, executives, board members, and contact information

View Contact ››

Please leave your comments here:

Popular Brands

Amazon
Asml
Acc
Apple
Abb
Amd
Abbvie
Att
Alfen
Adidas